APPLICATION OF BIOINFORMATICS FOR ANALYSIS OF CELLULAR SIGNAL TRANSDUCTION PATHWAYS
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-22-3-2020-g.9204Keywords:
bioinformatics analysis, chronic lymphocytic leukemia, FunCoup, signal transduction pathways, transcription factorsAbstract
Aim: to perform a search for cellular signaling pathways that are altered in transformed B-lymphocytes at chronic lymphocytic leukemia (CLL). Object and methods: the FunCoup algorithm was used to search for genomic functional associations for SMAD and STAT family proteins. Results: using the FunCoup algorithm to analyze the functional relationships of SMAD and STAT family proteins, it was shown that SMAD4 and STAT5A proteins play the main role in these cellular signaling pathways. Moreover, the analysis showed that these signaling pathways intersect with the pathways, regulating chromatin structure. It is likely that the inactivity of the certain areas of chromatin might cause the inability to transactivate the SMAD4- and STAT5-dependent genes in transformed B-cells at CLL.
References
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277–300.
Mahlich J, Okamoto S, Tsubota A. Cost of illness of japanese patients with chronic lymphocytic leukemia (CLL), and budget impact of the market introduction of ibrutinib. Pharmacoecon Open 2017; 1 (3): 195–202.
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67 (1): 7–30.
НКРУ (http://www.ncru.inf.ua.2018).
Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nature reviews Cancer 2016; 16 (3): 145–162.
Scarfo L, Dagklis A, Scielzo C, et al. CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? Semin Cancer Biol 2010; 20 (6): 384–390.
Gaidano G, Foa R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest 2012; 122 (10): 3432–8.
Gluzman DF, Sklyarenko LM, Koval SV, et al. Chronic lymphocytic leukemia and acute myeloid leukemias in structure of hematological malignancies in ukrainian population in post-chernobyl period. Oncology 2017; 19 (1): 33–44 (in Russian).
Filchenkov АА, Gluzman DF, Ivanivska ТS. New differentiative antigens of normal and neoplastic blood-forming and lymphoid cells (according to the materials of international working 10). Oncology 2019; 21 (2): 101–12 (in Russian).
Hallek M. Therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010; 23 (1): 85–96.
Haselager MV, Kater AP, Eldering E. Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing? Front Oncol 2020; 10: 592205. doi: 10.3389/fonc.2020.592205.
Sivina M, Xiao L, Kim E, et al. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia 2020. doi: 10.1038/s41375-020-01063-7.
Seifert M, Sellmann L, Bloehdorn J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 2012; 209 (12): 2183–98.
Dasgupta A, Mahapatra M, Saxena R. A study for proposal of use of regulatory T cells as a prognostic marker and establishing an optimal threshold level for their expression in chronic lymphocytic leukemia. Leuk Lymphoma 2015; 56 (6): 1831–8.
Matveeva A, Kovalevska L, Kholodnyuk I, et al. The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells. Exp Oncol 2017; 39 (4): 286–90.
Matveeva AS, Kovalevska LM Kashuba EV. SMAD4 transcription factor is localized in the cytoplasm of cells of patients with chronic lymphocytic leukemia (CLL). Factors in experimental evolution of organisms 2018; 22: 144–8.
Matveeva A, Kovalevska L, Polischuk A, Kashuba E. The IL-2-STAT5 pathway is blocked in chronic lymphocytic leukemia cells Онкология 2017; 19 (4): 247–53.
Matvieieva AS, Kovalevska LM, Ivanivska TS, et al. The STAT5 transcription factor in B-cells of patients with chronic lymphocytic leukemia. Biopolym Cell 2019; 35 (1): 30–8.
Ogata H, Goto S, Sato K, et al. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 1999; 27 (1): 29–34.
Alexeyenko A, Sonnhammer EL. Global networks of functional coupling in eukaryotes from comprehensive data integration. Genome Res 2009; 19 (6): 1107–16.
Schmitt T, Ogris C, Sonnhammer EL. FunCoup 3.0: database of genome-wide functional coupling networks. Nucleic Acids Res. 2014; 42 (Database issue): D380–388. doi: 10.1093/nar/gkt984.
Thambyrajah R, Fadlullah M, Proffitt M, et al. HDAC1 and HDAC2 Modulate TGF-beta Signaling during Endothelial-to-Hematopoietic Transition. Stem Cell Reports 2018; 10 (4): 1369–83.
Stojanovic N, Hassan Z, Wirth M, et al. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Oncogene 2017; 36 (13): 1804–15.
Itoh Y, Saitoh M, Miyazawa K. Smad3-STAT3 crosstalk in pathophysiological contexts. Acta Biochim Biophys Sin (Shanghai) 2018; 50 (1): 82–90.
Shi Y, Hata A, Lo R, et al. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997; 388 (6637): 87–93.
Zhao M, Mishra L, Deng C. The role of TGF-beta/SMAD4 signaling in cancer. Int J Biol Sci 2018; 14 (2): 111–23.
Peterson L, Kovyrshina T. Progression inference for somatic mutations in cancer. Heliyon 2017; 3 (4): e00277. doi: 10.1016/j.heliyon.2017.e00277.
McCarthy A, Chetty R. Smad4/DPC4. J Clin Pathol 2018; 71 (8): 661–4.
Hsu J, Sage J. Novel functions for the transcription factor E2F4 in development and disease. Cell Cycle 2016; 15 (23): 3183–90.
Hambleton S, Goodbourn S, Young D, et al. STAT2 deficiency and susceptibility to viral illness in humans. Proc Natl Acad Sci USA 2013; 110 (8): 3053–308.
Shahni R, Cale CM, Anderson G, et al. Signal transducer and activator of transcription 2 deficiency is a novel disorder of mitochondrial fission. Brain 2015; 1 38(Pt 10): 2834–46.
Ho J, Pelzel C, Begitt A, et al. STAT2 is a pervasive cytokine regulator due to its inhibition of STAT1 in multiple signaling pathways. PLoS Biol 2016; 14 (10): e2000117. doi: 10.1371/journal.pbio.2000117.
Heltemes-Harris LM, Farrar MA. The role of STAT5 in lymphocyte development and transformation. Curr Opin Immunol 2012; 24 (2): 146–52.
Dumas PY, Naudin C, Martin-Lanneree S, et al. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL. Haematologica 2019; 104 (10): 2017–027.
Malin S, McManus S, Busslinger M. STAT5 in B cell development and leukemia. Curr Opin Immunol 2010; 22 (2): 168–76.
Malin S, McManus S, Cobaleda C, et al. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat Immunol 2010; 11 (2): 171–9.
Rajala HL, Mustjoki S. STAT5b in LGL leukemia-a novel therapeutic target? Oncotarget 2013; 4 (6): 808–9.
Rajala HL, Eldfors S, Kuusanmaki H, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013; 121 (22): 4541–50.
Tolomeo M, Meli M, Grimaudo S. STAT5 and STAT5 Inhibitors in Hematological Malignancies. Anticancer Agents Med Chem 2019; 19 (17): 2036–4206.
de Araujo ED, Erdogan F, Neubauer HA, et al. Structural and functional consequences of the STAT5B(N642H) driver mutation. Nat Commun 2019; 10 (1): 2517.
Nowicki MO, Falinski R, Koptyra M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 104 (12): 3746–53.
Kollmann S, Grundschober E, Maurer B, et al. Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia. Leukemia 2019; 33 (7): 1583–97.
